Cargando…
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
Recent years have seen major advances in the management of metastatic renal cell carcinoma (mRCC). The tyrosine kinase and mammalian target of rapamycin inhibitors have resulted in disease control and improved survival for many patients with mRCC, but they have not led to preventive, predictive or p...
Autores principales: | Fisher, Rosalie, Larkin, James, Swanton, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375102/ https://www.ncbi.nlm.nih.gov/pubmed/22738081 http://dx.doi.org/10.1007/s13167-011-0137-3 |
Ejemplares similares
-
Inter and Intratumour Heterogeneity: A Barrier to Individualized Medical Therapy in Renal Cell Carcinoma?
por: Fisher, Rosalie, et al.
Publicado: (2012) -
Breast cancer genome heterogeneity: a challenge to personalised medicine?
por: Swanton, Charles, et al.
Publicado: (2011) -
Promoting predictive, preventive and personalised medicine: European event of global importance
por: Golubnitschaja, Olga, et al.
Publicado: (2011) -
Education in predictive, preventive and personalised medicine
Publicado: (2011) -
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care
por: Cerone, Maria Antonietta, et al.
Publicado: (2023)